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CORRESPONDENCE
The Predictive Value of Fibrotest vs. APRI for the Diagnosis
of Fibrosis in Chronic Hepatitis C
To the Editor:
Wai et al.1 developed indexes that identified significant fibrosis
in patients with chronic hepatitis C. These indexes, including as-
partate aminotransferase (AST) and platelets, had good discrimina-
tive power, as shown by areas under the receiver operating
characteristic curve (AUROC) of 0.82 for formula 1 predicting
fibrosis, 0.92 for formula 2 predicting cirrhosis, 0.83 for AST-
Platelets Ratio Index (APRI) for fibrosis, and 0.90 for cirrhosis. We
also validated a fibrosis index (Fibrotest; Biopredictive, Houilles,
France, US Patent Application Serial No. 09/687,459) with high
predictive values.2– 4
We sought to compare these indices by using data collected
retrospectively in 323 patients from our original population with
complete biochemical data.2 The prevalence of significant fibrosis
(F2–F4) was 41%, and cirrhosis (F4) was 13%. The mean
value (SE) for AST expressed in ULN was 1.71 (0.10) and platelets
count 192 (3) 109/L. AUROCs for significant fibrosis were 0.75
(0.03) for formula 1 and 0.74 (0.03) for APRI versus 0.83 (0.02)
for Fibrotest (P  0.03 vs. formula 1 and P  0.02 vs. APRI),5
suggesting that the latter has greater discriminative power. The
AUROCs for cirrhosis were 0.82 (0.04) for formula 2 and 0.80
(0.04) for APRI versus 0.92 (0.03) for Fibrotest (P  0.04 vs.
formula 2 and P  0.02 vs. APRI), suggesting that the latter has
greater discriminative power. There was a continuous, almost lin-
ear, relationship between Fibrotest and fibrosis stage, with signifi-
cant differences between stages that were not observed for the Wai1
indexes (Fig. 1).
In addition to superior diagnostic power, Fibrotest has several
other advantages. First, Fibrotest is not transaminase-dependent.
AST has poor sensitivity for fibrosis detection. When we apply the
sensitive cut-off recommended (1.00),1 we observe a 27% false-
negative rate for cirrhosis: 11 out of 41 patients with cirrhosis had
an APRI below 1.00. Among these 11 patients, 6 had normal AST
values. We observed 25 fibrotic patients out of 131 (19% false-
negative rate) who had APRI of 0.50 or below, the cut-off recom-
mended for excluding significant fibrosis. Among these 25 patients,
22 had normal AST. The so-called standardization of transami-
nases using the upper normal limit given by laboratories is hazard-
ous.6 To explain the differences in sensitivities observed in our
population versus the Wai population, we wonder if, in their cen-
ter, they were performing biopsies routinely in patients with nor-
mal transaminases, as we did in our center. This type of selection
could have overestimated the sensitivity of AST.
Second, we did not include platelet count in Fibrotest to develop an
index easily automated using minimal equipment. The components of
Fibrotest can be measured using a single autoanalyzer with minimal
variability.6
Third, Fibrotest has been validated in patients with human
immunodeficiency virus/HCV-coinfection,4 who often have
thrombocytopenia. Fibrotest is responsive to changes in fibrosis
attributable to interferon-based therapy.3 Finally, a combination of
alanine aminotransferase levels and Fibrotest (Actitest) accurately
predicts the severity of necroinflammatory activity.2,3 In conclu-
sion, these comparisons suggest that Fibrotest provides a more
accurate estimate of HCV-related fibrosis than the Wai indexes.1
Fig. 1. Notched box plots showing
the relationship between the stage of
fibrosis and (A) Fibrotest and (B) Wai et
al.1 formula index for significant fibrosis
(WaiF2) and (C) formula for cirrhosis
(WaiF4) and (D) ASAT-to-platelets ratio
index (APRI). The horizontal line inside
each box represents the median and the
width of each box and the 95% confi-
dence interval. Failure of the shaded
boxes to overlap signifies statistical sig-
nificance (P  0.05) between group
medians. The horizontal lines above and
below each box encompass the inter-
quartile range, and the vertical lines
from the ends of the box encompass the
adjacent values.
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Prospective comparisons in additional centers are warranted to
confirm this finding.












1. Wai CT, Greenson JK, Fontana RJ, Kalbfleish JD, Marrero JA, Conje-
evaram HS, Lok ASF. A simple noninvasive index can predict both signifi-
cant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY
2003;38:518–526.
2. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard
T. Biochemical markers of liver fibrosis in patients with hepatitis C virus
infection: a prospective study. Lancet 2001;357:1069–1075.
3. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical
surrogate markers of liver fibrosis and activity in a randomized trial of
peginterferon alfa-2b and ribavirin. HEPATOLOGY 2003;38:481–492.
4. Myers RP, Benhamou Y, Bochet M, Imbert-Bismut F, Thibault V, Ratziu
V, et al. Serum biochemical markers accurately predict liver fibrosis in HIV
and hepatitis C virus-coinfected patients. AIDS 2003;17:1–5.
5. Hanley JA, McNeil BJ. A method of comparing the areas under receiver
operating characteristic curves derived from the same cases. Radiology 1983;
148:839–843.
6. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-
Lamy P, Delaporte G, et al. A prospective assessment of the inter-laboratory
variability of biochemical markers of fibrosis (FibroTest) and activity (Ac-
tiTest) in patients with chronic liver disease. Comp Hepatol 2002;2:3–7.
T.P. is a consultant and has a capital interest in Biopredictive, the
company marketing FibroTest-Actitest.
Copyright © 2004 by the American Association for the Study of Liver Diseases.
Published online in Wiley InterScience (www.interscience.wiley.com).
DOI 10.1002/hep.20099
Reply:
We appreciate the interests expressed by Calvez and colleagues on
the use of the aspartate aminotransferase to platelet ratio index (APRI)
in predicting fibrosis in patients with chronic hepatitis C.1
We welcome external validation of APRI, because the ultimate
utility of any noninvasive model for prediction of hepatic fibrosis de-
pends on its practicality and validation by other investigators in a wide
range of patients. Several factors may account for the lower accuracy of
APRI in the cohort of French patients studied. First, we used an Ishak
fibrosis score, not a Metavir score. Second, there may have been dif-
ferences between the patient populations in the two studies. Our study
included consecutive treatment-naı̈ve chronic hepatitis C patients who
underwent liver biopsy at our center. Also, 26% of our patients were
non-Caucasians. The French study did not specify if any of the patients
had prior antiviral therapy, how many patients declined to participate,
or the ethnicity of their patients.2 Third, the proportion of patients
biopsied who had normal aminotransferases may be different. Patients
in our study had higher aspartate aminotransferase than those in the
study by Calvez and colleagues (mean: 2.3 vs. 1.7 times the upper limit
of normal). At our center, we recognize the risks of liver biopsy and the
generally benign course of patients with persistently normal amin-
otransferases; consequently, liver biopsy is performed only on selected
chronic hepatitis C patients who have normal aminotransferases. Fifty-
one (19%) patients in our study had normal aminotransferases at the
time of biopsy. We are surprised that Calvez and colleagues routinely
perform liver biopsies in patients with normal aminotransferases when
their group emphasizes the risks of liver biopsies and recommends that
liver biopsy should not be mandatory anymore.3
We recognize that the FibroTest has been validated in various
patient populations by Poynard and colleagues,2,3 but a recent study in
Australia using the FibroTest score computed from the same biochem-
ical analytes, age, and gender found a lower area under receiver oper-
ating characteristic curve (AUROC) of 0.739 and lower positive and
negative predictive values4 compared with other studies reported by
the French investigators. This highlights the importance of external
validation by other investigators in different patient populations with
test results from other laboratories.
We do not claim that APRI is the most accurate model for predic-
tion of significant fibrosis or cirrhosis in patients with chronic hepatitis
C. In fact, our study showed that APRI was slightly less accurate than
other models using complex formulas with more variables.1 The ad-
vantages of APRI include the use of a simple formula that is amenable
to mental calculation in the clinic, and the use of laboratory test results
that are routinely available to every clinician managing chronic hepa-
titis C patients. Thus, no additional blood collection or costs are
needed. We acknowledge that one limitation of APRI is the uncer-
tainty regarding the appropriate definition of the upper limit of normal
for aspartate aminotransferase. We agree that this is an important
question that needs to be resolved, not only for the application of APRI
but also for the evaluation of all forms of liver diseases.
ANNA S. LOK
CHUN-TAO WAI
University of Michigan Medical Center
Ann Arbor, MI
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Expression of Granzyme B in Viral Hepatitis in Patients With ALPS
To the Editor:
Apoptosis has transformed our understanding of the pathogenesis
of several diseases. Thus, autoimmune lymphoproliferative syndrome
(ALPS) is a rare disease due to genetic defects in the Fas apoptotic
pathway.1–3 Patients with ALPS display several clinical manifestations,
including lymphoproliferative disorders and systemic autoimmune
manifestations.1–3 Only one case in patients associating liver disease
with ALPS syndrome has been reported.4 We report here three patients
with APLS and chronic viral hepatitis.
As the Fas pathway is critical for the genesis of hepatitis,5 the
occurrence of hepatitis in a context of Fas deficiency raises the question
of the existence of an alternative lymphocytic-mediated apoptotic
pathway. To investigate this eventuality, we performed a case control
qualitative and quantitative study of Granzyme B (GzB) in intrahe-
patic cytotoxic lymphocytes in 3 patients with APLS and chronic viral
hepatitis.
Data concerning clinical presentations and main laboratory find-
ings are reported in Figure 1A. No antibody reflecting the existence of
autoimmune hepatitis6 was found. Fas deficiency diagnosis was based
on defective Fas-induced apoptosis assay as previously described.3 Se-
quencing of the Fas-encoding gene confirmed the diagnosis by show-
ing the presence of a heterozygous mutation as previously described.3
The paraffin-embedded formalin-fixed liver biopsies of the 3 patients
with ALPS were quantitatively analyzed for CD8 and GzB expression
and compared to 3 liver biopsies from patients with chronic hepatitis B
matched for histological activity index. Briefly, after heat antigen re-
trieval, slides were incubated with anti-GzB (Monosan, Uden, The
Netherlands) and anti-CD8 (Dako, Glostrup, Denmark) monoclonal
antibodies. Standard biotin-avidin complex immunoperoxidase was
Fig. 1. (A) Clinical and laboratory findings. AN, autoantibodies to nuclear antigens; Farr, autoantibodies to DNA; AP, autoantibodies to
phospholipids; AR, autoantibodies to erythrocytes; AP, autoantibodies to platelets; APMN, autoantibody to PMN; ASM, autoantibody to smooth
muscle; I, increased; N, normal; ND, not determined. CD4-CD8-/TcR /: Percentage of TcR / () lymphocytes expressing neither CD4 nor CD8
detected by cytometry. CD95 MoAb-induced apoptosis (%): Percentage of apoptotic cells. (B) Microphotographs of Granzyme B and CD8
immunostaining on serial sections of liver biopsy in Patient 3 with ALPS and chronic active hepatitis B (a,b) compared to a control chronic active
hepatitis B (c,d) without Fas deficiency. Arrows indicate granular and polarized granzyme B staining in lymphocyte cytoplasm in patients with ALPS
(a), or in control patients with chronic hepatitis B (c). (C) Granzyme B/ CD8 cells in ALPS patients and control patients.
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used with diaminobenzidine as chromogen for revelation. Quantifica-
tion of CD8 and GzB were performed as follows: for each liver biopsy
slide, 8 randomly selected 400 magnification fields (0.2 mm2) out of
portal tracts were analyzed for the number of CD8- and GzB-positive
cells. Mean and standard deviation of the number of GzB- and CD8-
positive cells per field for each biopsy and the ratio of the number of
GzB to CD8 cells was calculated for each case.
The number of CD8 lymphocyte was not statistically different in
ALPS cases compared to control cases (21  10 vs. 24  14; Wilcoxon
rank test: P  0.4). A 10  5-fold increase in the GzB-to-CD8 ratio
was found (Wilcoxon rank test: P  0.05). Details of the results are
presented in Figure 1C.
We show that when viral hepatitis occurs in a patient with Fas
deficiency, GzB-positive cells are overrepresented in the liver lympho-
cytic infiltrate compared to a control population, while there was no
difference in the number of CD8 lymphocytes in the infiltrate.
These observations show that:
1) Even if Fas is essential in the development of hepatitis,5 hepatitis
can occur in human even in the case of a defect in the Fas pathway.
2) The hyperactivation of GzB may counterbalance Fas deficiency
and explain, at least partially, the mechanism of viral hepatitis in pa-
tients with ALPS.
Nevertheless, GzB is activated during T-cell activation, and is
therefore an excellent marker of an activated T-cell phenotype. Thus,
other quantitative methods of GzB activity in the liver but also in
circulating lymphocytes are required to confirm the functional role of
GzB, and whether or not GzB overexpression is constitutive or de-
pends on certain stimuli such as viral infections. Further studies are
also required to confirm that overexpression of GzB can be met in
patients with other mutations than the one we describe here.
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FRANÇOISE LE DEIST, M.D., PH.D.




1. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative
syndromes: genetic defects of apoptosis pathways. Cell Death Differ 2003;
10:124–133.
2. Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N,
Fisher A, et al. Clinical, immunological, and pathological consequences of
Fas-deficient conditions. Lancet 1996;348:719–723.
3. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A,
de Villartay JP. Mutations in Fas associated with human lymphoprolifera-
tive syndrome and autoimmunity. Science 1995;268:1347–1349.
4. Pensati L, Costanzo A, Ianni A, Accapezzato D, Iorio R, Natoli G, Nisini R,
et al. Fas/APO1 mutations and autoimmune lymphoproliferative syndrome
in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997;113:
1384–1389.
5. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the
Fas ligand in the development of hepatitis. Nat Med 1997;3:409–413.
6. Czaja A, Homburger HA. Autoantibodies in liver disease. Gastroenterology
2001;120:239–249.
Copyright © 2004 by the American Association for the Study of Liver Diseases.
Published online in Wiley InterScience (www.interscience.wiley.com).
DOI 10.1002/hep.20100
Systemic, Renal, and Hepatic Hemodynamic Derangement in Cirrhotic Patients
With Spontaneous Bacterial Peritonitis
To the Editor:
We read with great interest the article by Ruiz-del-Arbol and col-
leagues.1 They report a lower cardiac index and a higher systemic
vascular resistance in patients with cirrhosis and spontaneous bacterial
peritonitis (SBP) who developed renal failure when compared with
SBP patients who did not develop renal failure. This difference in
cardiovascular function was accompanied by a significant increase in
plasma norepinephrine (NE) and plasma renin activity (PRA). A com-
bination of cirrhotic and septic cardiomyopathy was proposed as one
of the factors leading to circulatory dysfunction, where tumor necrosis
factor may play an important pathogenic role.
A decrease in left ventricular function using the Sarnoff curves2
has been found in cirrhotic patients exposed to sepsis.3 Because the
systemic inflammatory response syndrome could be found more
often in patients with renal failure, the decreased left ventricular
stroke work is quite logical. The argument against this concept is
the increase in systemic vascular resistance (SVR) found in patients
with renal failure; this is in contrast to findings in septic patients
with cirrhosis, where an extreme decrease in SVR could be found.4
Increases in SVR, NE, and PRA, as well as a decrease in renal
function, are common findings in the setting of elevated intra-
abdominal pressures,5 which may have been relevant in the patients
who were reported to have renal failure.
In addition, hypovolemia induces an increase in SVR, NE, and
PRA, decreases stroke volume, and leads to prerenal failure. Hypovo-
lemia must have played a relevant role in the patients reported, because
the right atrial pressure (3  3 mm Hg) as well as the pulmonary
capillary wedge pressure (PCWP; 5.7  4 mm Hg), an indirect pa-
rameter of left ventricular filling pressure, were reduced. The relevance
of hypovolemia for prognosis in sepsis was recently shown by Rivers
and collegues.6 With an early, goal-directed hemodynamic therapy—
consisting of infusion of cristalloids and/or colloids to normalize cen-
tral venous pressure to above 8 mm Hg; application of vasoconstrictors
to increase mean arterial pressure above 90 mm Hg; transfusion of red
cells until hematocrit is above 30%; and administration of inotropic
agents until a central venous oxygen saturation of above 80% is
achieved—mortality in septic patients could be significantly reduced.
HEPATOLOGY, Vol. 39, No. 3, 2004 CORRESPONDENCE 865
More confusing is the fact that examination of right atrial pressure
and PCWP revealed that patients who were not developing renal fail-
ure were also in a hypovolemic state. This might be caused by the high
variability in the interpretation of PCWP curves. Trottier and Raylor7
recently demonstrated high intra- and interobserver variabilities in the
measurement of PCWP, even in measurements made by physician
“experts” and physicians who commonly use the pulmonary artery
catheter. Therefore, because of the small numbers of patients studied,
hypovolemia with comparable ventricular compliance cannot be ex-
cluded totally as the explanation for the hemodynamic findings. In
addition, an elevation of intra-abdominal pressure may increase in-
trathoracic pressure; therefore, measured atrial pressures will not accu-
rately reflect transmural pressures.
In conclusion, the interesting findings of Ruiz-del-Arbol and col-
leagues may be caused by a combination of septic and cirrhotic cardio-
myopathy with hypovolemia combined with systemic inflammatory
response syndrome (SIRS) and increased intra-abdominal pressure.
The finding of high mortality is a further argument for an early, goal-
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Reply:
We are grateful to Dr. Lenz and coworkers for their interest in our
study.1 They remark on the complexity of circulatory dysfunction
leading to hepatorenal syndrome in patients with cirrhosis and spon-
taneous bacterial peritonitis (SBP). They suggest that hypovolemia is a
major event, since patients with hepatorenal syndrome showed low
right-atrial pressure and wedged capillary pulmonary pressure. We did
not observe an increase in peripheral vascular resistance in these pa-
tients, as Lenz et al. pointed out in their letter. In fact, no significant
changes in this parameter were observed in patients who did and did
not develop hepatorenal syndrome after SBP. Nevertheless, we agree
with their suggestion. As indicated in the discussion of the article, a
reduction in cardiac output in the absence of a significant increase in
cardiopulmonary pressure is consistent with a decreased venous return
to the heart. Also, the lack of increase in peripheral vascular resistance
in the setting of a decrease in cardiac output and a marked stimulation
of the renin-angiotensin system is consistent with an increase in arterial
vasodilation, probably in the splanchnic circulation, since it is well
known that in cirrhosis the vascular resistance in the renal,2 cutaneous,
muscular,3 and cerebral4 territories is directly related to the plasma
levels of renin. Therefore, the mechanism of circulatory dysfunction
associated with hepatorenal syndrome in patients with SBP is probably
the result of the simultaneous occurrence of progression of the arterial
vasodilation already present in nonazotemic patients with decompen-
sated cirrhosis together with impairment in cardiac function. This
contention is further supported by the high efficacy of the simulta-
neous treatment with plasma volume expansion and vasoconstrictors
in reversing hepatorenal syndrome,5 an effect rarely observed when
these measures are provided alone.
However, the suggestion by Lenz et al. that the decrease in cardiac
function is mainly related to hypovolemia is, in our opinion, an over-
simplification of the problem. The lack of increase in heart rate ob-
served in our study in patients developing type-1 hepatorenal
syndrome is striking, since there was an intense stimulation of the
sympathetic nervous system. This indicates a profound deterioration
of the chronotropic function of the heart. The effect of SBP on cardiac
inotropic function has never been explored.
We have previously shown that at the time of diagnosis of SBP,
plasma volume expansion with albumin reduces the incidence of he-
patorenal syndrome and hospital mortality by approximately 60%.6
The next step is to assess whether this figure could be improved by the
simultaneous administration of vasoconstrictors and albumin or by the
multiple treatments proposed by Lenz et al. in their letter.
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Pre-emptive Use of Lamivudine in Bone Marrow Transplantation
With Chronic Hepatitis B Virus Infection
To the Editor:
We read with much interest the article by Lau and colleagues.1
They reported on the pre-emptive use of lamivudine in bone marrow
transplant recipients to reduce the risk of hepatitis due to exacerbation
of hepatitis B. In their study, only one of 20 HbsAg-positive patients
had HBV-related hepatitis following transplantation. This patient re-
ceived 100 mg of lamivudine daily at least 1 week before allogeneic
hematopoietic cell transplantation, and this dosage was continued for
52 weeks after transplantation.
We recently encountered a 62-year-old Canadian woman of Fili-
pino origin with acute myelogeneous leukemia who was in need of
urgent life-saving bone marrow transplantation. The only possible
match identified for donation was her brother, a 34-year-old man with
known chronic hepatitis B infection: aspartate aminotransferase 28
U/L; alanine aminotransferase 56 U/L; bilirubin 10 mol/L; albumin
41 g/L: INR 0.93; HbsAg positive, HbeAg positive; HBV DNA 4262
pg/mL (Digene Hybrid Capture System). His liver biopsy showed
inflammation grade 1/4 and fibrosis stage 1/4.2
After the brother agreed to become a bone marrow donor, therapy
with 300 mg of lamivudine daily was started to decrease his HBV viral
load as rapidly as possible3 prior to bone marrow donation. Table 1
shows his serum HBV DNA levels sampled on a weekly basis while on
lamivudine therapy until his bone marrow was harvested on week 6.
To our surprise, the HBV DNA on the harvested tissue (peripheral
blood stem cells) after 6 weeks of lamivudine therapy was 1330 pg/mL
when it was negative in the serum. The recipient was HbsAg negative,
HBcAb positive, and HbsAb positive prior to bone marrow transplant
induction therapy, with no evidence of recurrent infection 6 months
following the transplantation. She has received prophylaxis with lami-
vudine and hepatitis B–immune globulins. While still on lamivudine,
the donor had a reappearance of HBV viremia 3 months after the
donation. Lamivudine was then discontinued, followed by a return to
baseline liver enzymes (alanine aminotransferase 54 U/L) and HBV
DNA (HBV DNA 3828 pg/mL) levels.
HBV exacerbation is a serious cause of morbidity and mortality in
patients receiving immunosuppression. We assumed that decreasing
the viral load in the donor tissue would decrease the risk of transmit-
ting the infection to the recipient. To our surprise, at a time when the
donor had a very low serum HBV DNA level, the cells harvested from
the bone marrow actually had a high viral load. We are unaware of any
data regarding changes in viremia in this cellular compartment in
patients receiving antiviral therapy. Although not tested, because of the
short duration we doubt the high viral load detected in the harvested
tissue was due to a lamivudine-resistant mutation. However, in retro-
spect one has to be concerned that the previous exposure to lamivudine
offered to the donor may help the selection of drug-resistant muta-
tions4 and lead to failure of future prophylaxis with lamivudine in the
recipient.
Fourteen of the donors (group 1 and 2; see Table 1) in the study by
Lau and colleagues were HbsAg-positive. We would be interested to
know if the authors compared serum and bone marrow HBV DNA
levels in some of their donors or if they have had a similar experience in
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Reply:
Deschenes et al. raise several important questions relating to the use
of hepatitis B surface antigen (HBsAg) positive donor for allogeneic
bone marrow transplantation. First, the use of HBsAg positive donors,
particularly those with a high pretransplant serum hepatitis B virus
(HBV) DNA level, has been associated with the development of post–
bone marrow transplantat HBV-related hepatitis.1 To this end, it is
highly justifiable to reduce the HBV viral load in the donor in an
attempt to reduce the subsequent risk of posttransplant hepatitis. In
addition, our center has adopted the policy of treating all bone marrow
transplant recipients of HBsAg positive donors with preemptive lami-
vudine to prevent posttransplant HBV-related liver diseases, irrespec-
tive of the recipients’ pretransplant HBV serological status. This has
Table 1.
Week of Lamivudine Therapy
Baseline 1 2 3 4 5 6
HBV DNA (pg/ml) 5319 419 66 20 13 12 Negative
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restricted us from studying the impact of the HBV DNA level in donor
marrow and subsequent posttransplant HBV-related liver diseases.
In our previous study, we did not test donor marrow samples for
HBV DNA.2 In our ongoing study, we have tested 10 pairs of
serum and mononuclear cells (derived from bone marrow) from the
HBsAg positive donors for HBV DNA level, using our in-house
quantitative assay based on polymerase chain reaction. Similar to
the experience of Deschenes et al., we have found a positive corre-
lation in HBV DNA level between serum and mononuclear cells.
However, from the follow-up paired serum-peripheral blood
mononuclear cells from these HBsAg positive donors treated with
lamivudine, our preliminary results showed that the response to
antiviral therapy is different in these 2 compartments, with a less
well-defined response in the mononuclear cell compartment. Spe-
cifically, in 4 HBsAg positive donors treated with lamivudine for 12
weeks, despite the lowering of serum HBV DNA to more than 3
log, the HBV DNA level in the paired PBMC remain unchanged,
suggesting that mononuclear cells from these treated HBsAg posi-
tive donor may still be infectious. Our study is investigating
whether the HBV DNA level in the peripheral blood mononuclear
cells will be lowered with prolonged lamivudine therapy. The dis-
crepancy of the antiviral response observed in the serum and mono-
nuclear cells’ HBV DNA level might be related to the replication
capacity of the HBV in the liver and mononuclear cells. Indeed, the
biological behavior of HBV within the mononuclear cells compart-
ment is still largely unknown. In keeping with this, the presence of
covalently closed circular DNA molecules, the key replicative in-
termediate in the synthesis of the viral pregenome and transcripts
during productive HBV infection, has not been convincingly dem-
onstrated in peripheral mononuclear cells.3 Hence, it is not surpris-
ing to observe a discrepancy between the reduction of HBV DNA
level in the serum, which reflects mainly active and productive
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Serum Laminin-2 and Hyaluronan Predict Severe Liver Fibrosis in Children With Chronic Hepatitis B
To the Editor:
Liver fibrosis and cirrhosis result from an imbalance of fibrogenesis
and fibrolysis. Serum levels of matrix components may be useful for
assessing hepatic matrix turnover or to predict fibrosis stage,1 which is
a problem in children in whom fibrosis markers are influenced by body
growth.1,2
We therefore determined serum levels of tenascin, laminin-2,
hyaluronan, collagen IV and VI, procollagen III N propeptide (PII-
INP), matrix metalloproteinase-2 (MMP-2), tissue inhibitor of
matrix metalloproteinase-1 (TIMP-1), and the MMP-9/TIMP-1
complex after an overnight fast in 47 children (mean age 8 years;
range 4 –16) with chronic HBe-Ag positive hepatitis B prior to
interferon- therapy. Measurements were performed on the Bayer
Immuno 1 Analyzer (Bayer AG, Leverkusen, Germany) using flu-
orescein and alkaline phosphatase–labeled monoclonal antibodies
to the protein antigens.3,4 Liver biopsies were obtained at the time
of serum sampling, and the protocol was approved by the ethics
committee of the Medical University of Białystok. Fibrosis and
inflammation were assessed by a single-blinded pathologist (M. S.
Ł). Staging was according to Ishak and colleagues (early fibrosis:
stage 1–3 vs. advanced fibrosis: stage 4 – 6),5 METAVIR,6 and Batts
and Ludwig (stage 1–2 vs. 3– 4).7 Receiver operating characteristics
(ROC, ACCUROC, Canada) and area under curve analysis were
measured to calculate the power of the markers to detect advanced
fibrosis.
Seven,5 nine,6 or eight7 children had advanced fibrosis. Using
the Batts and Ludwig score, serum hyaluronan above 27 ng/mL had
a sensitivity of 100% and a specificity of 50%, and serum laminin-2
above 34.9 ng/mL had a sensitivity of 62.5% and a specificity of
92.1% to predict advanced fibrosis. The combination of both
markers was superior. With laminin-2 above 34.9 ng/mL and/or
hyaluronan above 27 ng/mL, the area under curve was 0.8429 (P 
.003), the sensitivity was 87.5%, and the specificity was 73%.
Similar results for single and combined markers were obtained for
the Ishak and METAVIR scores (Fig. 1). Using the combined
markers and the Batts and Ludwig score, 28 and 6 out of the 45/47
children (for two children only one of the two parameters was
determined) could be allocated with 100% confidence either to the
group with mild or severe fibrosis, respectively, potentially avoiding
biopsy in 34 (75.6%) of children. All other serum markers and their
combinations yielded a lower predictive power. None of the mark-
ers was a good predictor of histologic inflammation.
Liver biopsy remains the gold standard for the grading and
staging of liver disease. However, this risky procedure is dispensible
for children who have only minor fibrosis. Notably, among a broad
panel of serum fibrosis markers, only hyaluronan and laminin-2
accurately predicted the presence of advanced fibrosis. Other serum
fibrosis markers were not deemed useful in children because they
are influenced by body growth (PIIINP and procollagen IV) or
bone metabolism (procollagen I).1,2 The predictive power of hya-
luronan and laminin-2 may be due to their short biologic half life
(hyaluronan)8 or their selective expression in fibrosing sinusoidal
basement membranes (laminin-2),9 which precludes a major con-
tribution by (growing) bones or ubiquitous interstitial tissues. The
usefulness of these parameters for children with other chronic liver
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diseases (e.g., chronic hepatitis C, biliary atresia) has yet to be
demonstrated.
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Fig. 1. ROC analysis for the combination of serum hyaluronan and
serum laminin-2 to predict severe fibrosis, according to the three staging
systems described in the text. Solid line, HALam (BATTS); broken line,
HALam (ISHAK); dotted line, HALam (METAVIR).
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